Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT00114894 |
Other study ID # |
0311M54041 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 3
|
First received |
|
Last updated |
|
Start date |
April 2004 |
Est. completion date |
February 2006 |
Study information
Verified date |
April 2023 |
Source |
University of Minnesota |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Jellyfish stings are a common occurrence among ocean-goers worldwide with an estimated 150
million envenomations annually. Fatalities and hospitalizations occur annually, particularly
in the Indo-Pacific regions. A new topical jellyfish sting inhibitor based on the mucous
coating of the clown fish prevents 85% of jellyfish stings in laboratory settings. The field
effectiveness is unknown. This is a field test to determine the real world effectiveness.
Description:
Jellyfish stings are a common occurrence among ocean-goers worldwide with an estimated 150
million envenomations annually. Fatalities and hospitalizations occur annually, particularly
in the Indo-Pacific regions. A new topical jellyfish sting inhibitor based on the mucous
coating of the clown fish prevents 85% of jellyfish stings in laboratory settings.
Clown fish inhabit within the tentacles of sea anemones, which have stinging cells similar to
those of jellyfish, yet clown fish are not stung by the sea anemones. In controlled
laboratory environments, the jellyfish sting inhibitor, Safe Sea™ when applied to volunteers'
arms, prevented 100% of Chrysaora fuscescens stings and 70% of Chiropsalmus quadrumanus
stings. Of the C. quadrumanus stings that occurred, their intensity was diminished. The field
effectiveness is unknown. This is a field test to determine the real world effectiveness of
Safe Sea to prevent jellyfish stings.